The bitterness of racemic praziquantel (PZQ) currently constrains its use as an in-feed treatment against monogenean flukes in finfish aquaculture. In an effort to increase the palatability of diets containing racemic PZQ for yellowtail kingfish, the palatability and efficacy of 2 forms of racemic PZQ (powder or powder within microcapsules) against natural infestations of skin and gill flukes were compared using 2 different dietary application methods (incorporated within the pellet mash prior to extrusion or surface-coated after extrusion) at active dietary inclusion levels of 8, 16 and 25 g kg-1 in large (3.5-4 kg) yellowtail kingfish. There was no clear benefit of incorporating PZQ into diets prior to extrusion. PZQ microcapsules improved the palatability of PZQ-containing diets but did not completely mask the bitter flavour. At the lowest active dietary inclusion level of 8 g kg-1, ingestion of the diet containing PZQ microcapsules was equal to the control and significantly better than that containing PZQ powder. At an inclusion level of 16 g kg-1, ingestion of the PZQ microcapsule diet was significantly better than that containing the same inclusion of PZQ powder but significantly lower than the control. Consumption of the diet containing 25 g kg-1 of PZQ microcapsules was poor. All fish consuming medicated feeds had a significant reduction in flukes relative to control fish; however, efficacy data and blood serum analysis suggested that diets containing PZQ microcapsules had lower bioavailability than those containing PZQ powder.

Download full-text PDF

Source
http://dx.doi.org/10.3354/dao02740DOI Listing

Publication Analysis

Top Keywords

pzq powder
16
pzq microcapsules
16
dietary inclusion
12
inclusion level
12
yellowtail kingfish
12
pzq
12
dietary application
8
palatability efficacy
8
racemic pzq
8
prior extrusion
8

Similar Publications

Amorphous Solid Dispersion Formation for Enhanced Release Performance of Racemic and Enantiopure Praziquantel.

Mol Pharm

October 2024

Department of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.

Praziquantel (PZQ) is the treatment of choice for schistosomiasis, which affects more than 250 million people globally. Commercial tablets contain the crystalline racemic compound (-PZQ) which limits drug dissolution and oral bioavailability and can lead to unwanted side effects and poor patient compliance due to the presence of the -enantiomer. While many approaches have been explored for improving PZQ's dissolution and oral bioavailability, studies focusing on investigating its release from amorphous solid dispersions (ASDs) have been limited.

View Article and Find Full Text PDF

This paper aims to evaluate the product contamination by elemental impurities during the mechanochemical synthesis of praziquantel (PZQ) co-crystal, polymeric dispersion and cyclodextrin complex by grinding. To assess that, PZQ was co-ground with malic acid (MA), Poloxamer F-127 (F-127) and hydroxypropyl-β-cyclodextrin (HPβCD) in high-energy vibrational mills using stainless steel and agate grinding tools, applying different processing time (30 and 90 min). Differential scanning calorimetry and X-ray powder diffraction confirmed the formation of the targeted products, regardless of applied processing time and grinding tool type.

View Article and Find Full Text PDF

In Vivo Evaluation of an Antibody-Functionalized Lipoidal Nanosystem for Schistosomiasis Intervention.

Pharmaceutics

July 2022

Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 7 York Road, Parktown 2193, South Africa.

This study employed nanotechnological techniques to design and develop a praziquantel nanoliposomal (NLP) system and surface-functionalized the NLP with anti-calpain antibody (anti-calpain-NLP) for targeted praziquantel (PZQ) delivery in the treatment of schistosomiasis. Anti-calpain-NLPs were prepared and validated for their physicochemical parameters, in vitroand in vivotoxicity, drug entrapment efficiency (DEE), drug loading capacity (DLC), drug release, and parasitological cure rate. The particle sizes for the formulated nanoliposomes ranged from 88.

View Article and Find Full Text PDF

Nanoconfinement of a Pharmaceutical Cocrystal with Praziquantel in Mesoporous Silica: The Influence of the Solid Form on Dissolution Enhancement.

Mol Pharm

February 2022

Centro de Investigaciones Químicas, Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Av. Universidad 1001, Cuernavaca 62209, México.

Nanoconfinement is a recent strategy to enhance solubility and dissolution of active pharmaceutical ingredients (APIs) with poor biopharmaceutical properties. In this work, we combine the advantage of cocrystals of racemic praziquantel (PZQ) containing a water-soluble coformer (i.e.

View Article and Find Full Text PDF

Two new solvates of the widely used anthelminthic Praziquantel (PZQ) were obtained through mechanochemical screening with different liquid additives. Specifically, 2-pyrrolidone and acetic acid gave solvates with 1:1 stoichiometry (PZQ-AA and PZQ-2P, respectively). A wide-ranging characterization of the new solid forms was carried out by means of powder X-ray diffraction, differential scanning calorimetry, FT-IR, solid-state NMR and biopharmaceutical analyses (solubility and intrinsic dissolution studies).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!